REKA Statistics

Total Valuation

Rekah Pharmaceutical Industry has a market cap or net worth of ILS 163.12 million. The enterprise value is 296.29 million.

Market Cap	163.12M
Enterprise Value	296.29M

Important Dates

The next estimated earnings date is Tuesday, November 26, 2024.

Earnings Date	Nov 26, 2024
Ex-Dividend Date	n/a

Share Statistics

Rekah Pharmaceutical Industry has 11.41 million shares outstanding. The number of shares has increased by 4.37% in one year.

Current Share Class	n/a
Shares Outstanding	11.41M
Shares Change (YoY)	+4.37%
Shares Change (QoQ)	+4.75%
Owned by Insiders (%)	40.54%
Owned by Institutions (%)	2.88%
Float	1.87M

Valuation Ratios

The trailing PE ratio is 25.23.

PE Ratio	25.23
Forward PE	n/a
PS Ratio	0.53
PB Ratio	0.97
P/TBV Ratio	n/a
P/FCF Ratio	13.34
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 5.94, with an EV/FCF ratio of 24.23.

EV / Earnings	43.53
EV / Sales	0.91
EV / EBITDA	5.94
EV / EBIT	16.50
EV / FCF	24.23

Financial Position

The company has a current ratio of 1.49, with a Debt / Equity ratio of 0.82.

Current Ratio	1.49
Quick Ratio	0.83
Debt / Equity	0.82
Debt / EBITDA	2.77
Debt / FCF	11.33
Interest Coverage	2.37

Financial Efficiency

Return on equity (ROE) is 4.11% and return on invested capital (ROIC) is 3.49%.

Return on Equity (ROE)	4.11%
Return on Assets (ROA)	2.38%
Return on Capital (ROIC)	3.49%
Revenue Per Employee	759,628
Profits Per Employee	15,941
Employee Count	427
Asset Turnover	0.68
Inventory Turnover	2.56

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -7.83% in the last 52 weeks. The beta is 0.04, so Rekah Pharmaceutical Industry's price volatility has been lower than the market average.

Beta (5Y)	0.04
52-Week Price Change	-7.83%
50-Day Moving Average	1,390.62
200-Day Moving Average	1,404.33
Relative Strength Index (RSI)	52.01
Average Volume (20 Days)	1,882

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Rekah Pharmaceutical Industry had revenue of ILS 324.36 million and earned 6.81 million in profits. Earnings per share was 0.57.

Revenue	324.36M
Gross Profit	75.45M
Operating Income	18.06M
Pretax Income	9.12M
Net Income	6.81M
EBITDA	43.28M
EBIT	18.06M
Earnings Per Share (EPS)	0.57

Full Income Statement

Balance Sheet

The company has 5.45 million in cash and 138.58 million in debt, giving a net cash position of -133.13 million or -11.66 per share.

Cash & Cash Equivalents	5.45M
Total Debt	138.58M
Net Cash	-133.13M
Net Cash Per Share	-11.66
Equity (Book Value)	169.15M
Book Value Per Share	14.80
Working Capital	73.97M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 24.14 million and capital expenditures -11.92 million, giving a free cash flow of 12.23 million.

Operating Cash Flow	24.14M
Capital Expenditures	-11.92M
Free Cash Flow	12.23M
FCF Per Share	1.07

Full Cash Flow Statement

Margins

Gross margin is 23.26%, with operating and profit margins of 5.57% and 2.10%.

Gross Margin	23.26%
Operating Margin	5.57%
Pretax Margin	2.81%
Profit Margin	2.10%
EBITDA Margin	13.34%
EBIT Margin	5.57%
FCF Margin	3.77%

Dividends & Yields

Rekah Pharmaceutical Industry does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.37%
Shareholder Yield	-4.37%
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Rekah Pharmaceutical Industry has an Altman Z-Score of 1.5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.5
Piotroski F-Score	n/a